肝苏片联合恩替卡韦对重症乙肝患者治疗效果及对患者免疫功能的影响  

The therapeutic effect of Gansu tablet combined with entecavir on severe hepatitis B patients and its influence on their immune function

作　　者：高爱华[1] 王新丽[2] 孙艳芹 姜清河 刘霞 GAO Aihua;WANG Xinli;SUN Yanqin;JIANG Qinghe;LIU Xia(Hepatology Department,Cangzhou Infectious Disease Hospital,Cangzhou,Hebei 061001,China;Outpatient Department,Cangzhou Infectious Disease Hospital,Cangzhou,Hebei 061001,China;Tuberculosis Department,Cangzhou Infectious Disease Hospital,Cangzhou,Hebei 061001,China)

机构地区：[1]河北省沧州市传染病医院肝病一科,河北沧州061001 [2]河北省沧州市传染病医院肝病科 [3]河北省沧州市传染病医院简易门诊 [4]河北省沧州市传染病医院结核科

出　　处：《公共卫生与预防医学》2021年第2期133-136,共4页Journal of Public Health and Preventive Medicine

基　　金：河北省中医药管理局科研基金项目(2019310)。

摘　　要：目的探究肝苏片联合恩替卡韦对重症乙肝患者的治疗效果及对患者免疫功能的影响。方法选取2018年1月至2019年1月于沧州市传染病医院接受治疗的重症乙肝患者108例,随机分为恩替卡韦组、联合治疗组各54例,恩替卡韦组患者使用恩替卡韦进行治疗,联合治疗组患者使用肝苏片联合恩替卡韦进行治疗。对两组患者谷草转氨酶(AST)、谷氨酰转肽酶(GGT)、丙转氨酶(ALT)、纤维蛋白原(FIB)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)水平进行检测;流式细胞仪检测T淋巴细胞亚群水平,对比两组患者治疗效果及不良反应。结果治疗后联合治疗组患者AST、GGT、ALT、APTT、PT、CD8^(+)水平低于恩替卡韦组,FIB、CD4^(+)、CD3^(+)水平、治疗总有效率高于恩替卡韦组(P<0.05)。联合治疗组不良反应发生率略高于恩替卡韦组,但差异无统计学意义(P>0.05)。结论使用肝苏片联合恩替卡韦对重症乙肝患者进行治疗,能够提升患者肝功能、凝血功能及免疫功能,治疗效果显著,具有一定临床应用价值。Objective To explore the therapeutic effect of Gansu tablets combined with entecavir on patients with severe hepatitis B and the effect on patients’immune function.Methods A total of 108 cases of severe hepatitis B patients who were treated in our hospital from January 2018 to January 2019 were randomly divided into two groups:entecavir group and combination treatment group,54 cases each.Entecavir group was treated with entecavir,and combination treatment group was treated with Gansu tablets and entecavir.The levels of AST,GGT,alt,FIB,APTT,Pt,GSH Px,LPO and MDA in serum were measured by enzyme-linked immunosorbent assay.T-lymphocyte subsets were measured by cell analyzer.The therapeutic effect and adverse reactions were compared between the two groups.Results The levels of AST,GGT and ALT in the combined treatment group were significantly lower than those in the entecavir group(P<0.05).After treatment,the FIB level of patients in the combined treatment group was higher than that in the entecavir group,and the APTT and Pt levels were lower than those in the entecavir group(P<0.05).After treatment,the GSH PX level of the combined treatment group was higher than that of entecavir group,and the LPO and MDA levels were lower than that of entecavir group(P<0.05).After treatment,the level of CD8^(+)was lower than that of entecavir group,and the level of CD4^(+)and CD3^(+)was higher than that of entecavir group(P<0.05).The total effective rate of the combined treatment group was higher than that of the entecavir group(P<0.05).The incidence of adverse reactions in the combined treatment group was slightly higher than that in the entecavir group,but the difference was not statistically significant(P>0.05).Conclusion The use of Gansu tablets combined with entecavir in the treatment of severe hepatitis B patients was able to improve liver function,improve coagulation function,reduce oxidative stress injury,and improve the immune function of patients,demonstrating a potential clinical application value.

关 键 词：肝苏片 恩替卡韦 重症乙肝 免疫功能 

分 类 号：R183[医药卫生—流行病学]